Ocular Metastasis Survival Shows No Gains Since 1979
A retrospective study of 569 patients found median survival after an ocular metastasis diagnosis has not improved over four decades.
Updated on Nov. 3, 2026 in Cancer
Researchers reported that survival for patients with cancer spread to the eye did not improve between 1979 and 2018. The study, published October 8, 2026, in the American Journal of Ophthalmology, found a median survival of 8.2 months after diagnosis.
Why it matters
The findings suggest that treatment advances over four decades have not translated into longer survival for patients whose cancer has metastasized to the eye. Clinicians and patients facing this diagnosis may need to weigh expectations accordingly.
The study covered 569 patients with 727 affected eyes, with breast cancer (38.3%) and lung cancer (27.9%) as the most common sources. Median survival was 12.4 months for breast cancer patients and 4.8 months for lung cancer patients, and the source does not explain the underlying causes of these differences.
The players
American Journal of Ophthalmology
A peer-reviewed medical journal publishing research on eye diseases and ophthalmic care.
The details
Investigators analyzed clinical characteristics, primary cancer sites, ocular involvement, treatment responses, and overall survival for patients treated at a single ocular oncology practice. They compared outcomes between patients diagnosed in 1979-1998 and those diagnosed in 1999-2018.
Timeline
1979-1998: First comparison cohort of patients diagnosed with ocular metastases.
1999-2018: Second comparison cohort of patients diagnosed with ocular metastases.
October 8, 2026: Study published online in the American Journal of Ophthalmology.
Health Landscape
The findings add to a body of cancer research asking whether broad treatment advances have improved outcomes for metastatic disease. Ocular metastases appear to be a case where survival has remained flat across four decades of care.
Patients diagnosed with ocular metastases face a median survival of about eight months, which may shape decisions about treatment goals and planning. Those with a breast or lung cancer origin should discuss these outcomes with their oncology team.
The takeaway
Survival for ocular metastases has not improved over four decades in this single-practice study, underscoring the need for research into more effective treatments. Patients and families should seek detailed prognostic information from their oncology teams.
Further reading
Explore more on Cancer to see how metastatic disease outcomes are studied and treated.
Source note: This article includes information reported by Ophthalmology Advisor.
